Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732913 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin's Lymphomas

Interventions

DRUG: Placebo
DRUG: Rituximab
DRUG: Idelalisib

Sponsor

Gilead Sciences